Craft

Biohit

Stock Price

€2.5

2024-10-29

Market Capitalization

€38 M

2024-10-29

Revenue

€15.7 M

FY, 2025

Biohit Summary

Company Summary

Overview
Biohit, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. Its diagnostic tests product range includes the blood-sample based GastroPanel test for diagnosing diseases of the stomach and associated risks; quick tests for the diagnosis of lactose intolerance, Helicobacter pylori infection, and Celiac disease; and ColonView for the early detection of fecal occult blood. The Company's diagnostic tests are also used for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, and gastroesophageal reflux disease, as well as deficiencies of vitamin B12, calcium, and iron.
Type
Public
Status
Active
Founded
1988
HQ
Helsinki, FI | view all locations
Website
https://www.biohithealthcare.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Semi Korpela
  • Liu Feng

    Liu Feng, Director

    • Osmo Suovaniemi

      Osmo Suovaniemi, Chairman of the Board

      • Ilari Patrakka

        Ilari Patrakka, Sales & Marketing Director

      LocationsView all

      3 locations detected

      • Helsinki HQ

        Finland

        Laippatie 1

      • Milano, Lombardia

        Italy

        Via Carlo Boncompagni, 3

      • Cheshire, England

        United Kingdom

        Pioneer Business Park, Pioneer House, North Rd

      Biohit Financials

      Summary Financials

      Revenue (FY, 2025)
      €15.7M
      Gross profit (FY, 2025)
      €10.8M
      Net income (FY, 2025)
      €2.7M
      Cash (FY, 2025)
      €3.5M
      EBIT (FY, 2025)
      €3.1M
      Enterprise value
      $36.0M

      Footer menu